Ranbaxy, Orchid Deal Seen Close To All-India Merger
This article was originally published in PharmAsia News
India's Ranbaxy Group is considered close to a public offer for another Indian firm, Orchid Chemicals & Pharmaceuticals. The offer would be made through Solrex Pharmaceuticals, which is linked to Ranbaxy and which has increased its shares in Orchid to 14.7 percent. In India, a 15 per cent ownership is considered an offer to public shareholders and an intension to have a voice in the running of a company such as Orchid. Ranbaxy is seen as a potential beneficiary of Orchid's portfolio of antibiotics. Neither firm would comment. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.